GlassScriptPhysician profile
Catherine A Duncan
NPI 1396778262
$896.46
in general payments reported to CMS, 2019-2025
23 companies · $55.15 in 2025
The $55.15 reported for 2025 was less than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
See the full distribution for Physical Medicine & Rehabilitation
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $296 · 2020: $248 · 2021: $169 · 2022: $96.64 · 2023: $31.82 · 2025: $55.15.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $86.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $86.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $97.77 | 2019-2021 | |
| Collegium Pharmaceutical, INC. | $86.22 | 2020-2023 | Xtampza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $78.25 | 2020-2021 | |
| Lilly USA, LLC | $73.68 | 2019-2022 | |
| Abbvie INC. | $59.21 | 2022-2023 | Ubrelvy |
| Haemonetics Corporation | $55.15 | 2025 | Teg6s Hemostasis System |
| Teva Pharmaceuticals USA, INC. | $53.79 | 2019-2020 | |
| Indivior INC. | $46.99 | 2019 | |
| Shionogi INC | $44.10 | 2019 | |
| Amgen INC. | $38.23 | 2019-2020 | |
| Redhill Biopharma INC. | $32.04 | 2021 | |
| Fidia Pharma USA INC. | $26.82 | 2019-2020 | |
| Allergan, INC. | $26.33 | 2020 | |
| Sentynl Therapeutics, INC. | $26.04 | 2019 | |
| Biodelivery Sciences International, INC. | $24.46 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zyla Life Sciences, INC. | $23.91 | 2019 | |
| Medtronic USA, INC. | $19.81 | 2019 | |
| Bioventus LLC | $19.26 | 2021 | |
| Daiichi Sankyo INC. | $14.31 | 2019 | |
| Nevro Corp. | $13.02 | 2021 | |
| Vertos Medical, INC. | $12.70 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $12.43 | 2021 | |
| Promius Pharma LLC | $11.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Duncan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.